409 related articles for article (PubMed ID: 21733647)
1. Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
Panjari M; Davis SR
Maturitas; 2011 Sep; 70(1):22-5. PubMed ID: 21733647
[TBL] [Abstract][Full Text] [Related]
2. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.
Archer DF
J Steroid Biochem Mol Biol; 2015 Jan; 145():139-43. PubMed ID: 25201455
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
[TBL] [Abstract][Full Text] [Related]
4. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):907-22. PubMed ID: 19436225
[TBL] [Abstract][Full Text] [Related]
5. DHEA for postmenopausal women: a review of the evidence.
Panjari M; Davis SR
Maturitas; 2010 Jun; 66(2):172-9. PubMed ID: 20089375
[TBL] [Abstract][Full Text] [Related]
6. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Bérubé R; Bélanger P; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):897-906. PubMed ID: 19436226
[TBL] [Abstract][Full Text] [Related]
7. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy.
Crandall C
J Womens Health (Larchmt); 2002 Dec; 11(10):857-77. PubMed ID: 12626086
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
Archer DF; Labrie F; Montesino M; Martel C
J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
[TBL] [Abstract][Full Text] [Related]
9. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Martel C; Balser J
Gynecol Endocrinol; 2010 Jul; 26(7):524-32. PubMed ID: 20459349
[TBL] [Abstract][Full Text] [Related]
10. DHEA, important source of sex steroids in men and even more in women.
Labrie F
Prog Brain Res; 2010; 182():97-148. PubMed ID: 20541662
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
[TBL] [Abstract][Full Text] [Related]
12. Effect of raloxifene on sexual function in postmenopausal women.
Kessel B; Nachtigall L; Plouffe L; Siddhanti S; Rosen A; Parsons A
Climacteric; 2003 Sep; 6(3):248-56. PubMed ID: 14567773
[TBL] [Abstract][Full Text] [Related]
13. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
Al-Baghdadi O; Ewies AA
Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):923-31. PubMed ID: 19424093
[TBL] [Abstract][Full Text] [Related]
15. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
Bachmann G; Bobula J; Mirkin S
Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
[TBL] [Abstract][Full Text] [Related]
16. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
Portman DJ; Labrie F; Archer DF; Bouchard C; Cusan L; Girard G; Ayotte N; Koltun W; Blouin F; Young D; Wade A; Martel C; Dubé R;
Menopause; 2015 Dec; 22(12):1289-95. PubMed ID: 25968836
[TBL] [Abstract][Full Text] [Related]
17. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
Martel C; Labrie F; Archer DF; Ke Y; Gonthier R; Simard JN; Lavoie L; Vaillancourt M; Montesino M; Balser J; Moyneur É;
J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
[TBL] [Abstract][Full Text] [Related]
18. [Local estrogen therapy--clinical implications--2012 update].
Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
[TBL] [Abstract][Full Text] [Related]
19. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
[TBL] [Abstract][Full Text] [Related]
20. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy.
Dugal R; Hesla K; Sørdal T; Aase KH; Lilleeidet O; Wickstrøm E
Acta Obstet Gynecol Scand; 2000 Apr; 79(4):293-7. PubMed ID: 10746845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]